BBP:NYE-Virtus LifeSci Biotech Products ETF (USD)

ETF | Health |

Last Closing

USD 60.9318

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

1.18K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-16 )

ETFs Containing BBP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 4.89% 67% D+ 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.89% 48% F 35% F
Trailing 12 Months  
Capital Gain 23.79% 86% B+ 69% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.79% 81% B- 63% D
Trailing 5 Years  
Capital Gain 52.51% 100% F 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 52.51% 81% B- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 8.65% 86% B+ 62% D
Dividend Return 8.65% 86% B+ 56% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 18.68% 52% F 58% F
Risk Adjusted Return 46.32% 76% C+ 63% D
Market Capitalization 0.02B 20% F 12% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.